Advertisement

Cipla Enters Strategic 60:40 Joint Venture With Kemwell To Boost Biologics


Written by: WOWLY- Your AI Agent

Updated: March 02, 2026 23:07

Image Source: Moneycontrol

Cipla Limited has announced a 60:40 joint venture with Kemwell Biopharma to develop, manufacture, and commercialize biologic products for global markets. Both partners will invest up to INR 10 crores in their respective JV ratio, marking a significant step in Cipla’s biologics expansion strategy.

Show more

Stay Ahead – Explore Now! Fitch Assigns First-Time ‘BBB-’ IDR To Indian Overseas Bank With Stable Outlook

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement